8-KRegulation FDExhibits & Filings

Merck & Co., Inc. 8-K Report, Regulation FD Disclosure (Mar 18, 2008)

Filed March 18, 2008For Securities:MRK

Summary

This 8-K filing from Merck & Co., Inc. (MRK), dated March 17, 2008, primarily serves to disclose an updated set of Frequently Asked Questions and Answers (FAQs) relevant to investors. These FAQs are provided by Schering-Plough Corporation, indicating a potential focus on aspects related to that company's operations or a potential transaction involving both entities. Investors should review these FAQs for insights into management's current perspectives on business matters, strategic initiatives, or financial performance that Schering-Plough deems important for disclosure.

Key Highlights

  • 1Disclosure of updated Frequently Asked Questions and Answers (FAQs) from Schering-Plough Corporation.
  • 2The filing is primarily for Regulation FD disclosure purposes.
  • 3The FAQs are dated March 17, 2008, and are available on the Schering-Plough website.
  • 4Investors are directed to the Schering-Plough investor relations section for the FAQs.
  • 5Merck & Co., Inc. is furnishing these FAQs as Exhibit 99.1 to the 8-K filing.
  • 6Schering-Plough undertakes no obligation to update the provided FAQs.
  • 7Investors should be mindful of the date of the information contained within the FAQs.

Frequently Asked Questions

The primary purpose of this 8-K filing is to disclose updated Frequently Asked Questions and Answers (FAQs) from Schering-Plough Corporation, as part of Merck & Co., Inc.'s Regulation FD disclosure.

The specific FAQs, dated March 17, 2008, are furnished as Exhibit 99.1 to this 8-K filing and are also available on the Schering-Plough website at www.schering-plough.com under 'investor relations/investor FAQs'.

No, the filing states that Schering-Plough Corporation undertakes no obligation to update the FAQs. Investors should refer to the date of the information provided.

While the FAQs are from Schering-Plough, their disclosure via Merck's 8-K suggests they may contain information relevant to Merck investors, potentially due to ongoing discussions, a proposed transaction, or shared business interests between the two companies at that time.